The price of Artiva Biotherapeutics Inc (NASDAQ:ARTV) shares last traded on Wall Street fell -6.67% to $1.68.
ARTV stock price is now -20.07% away from the 50-day moving average and -77.08% away from the 200-day moving average. The market capitalization of the company currently stands at $40.93M.
On December 30, 2024, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $20, while ‘Wedbush’ rates the stock as ‘Outperform’
In other news, RA CAPITAL MANAGEMENT, L.P., Director bought 8,333,333 shares of the company’s stock on Jul 22 ’24. The stock was bought for $99,999,996 at an average price of $12.00. Upon completion of the transaction, the Director now directly owns 8,693,579 shares in the company, valued at $14.61 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 22 ’24, 10% Owner 5AM Partners VI, LLC bought 833,333 shares of the business’s stock. A total of $9,999,996 was incurred on buying the stock at an average price of $12.00. This leaves the insider owning 1,182,054 shares of the company worth $1.99 million. A total of 49.52% of the company’s stock is owned by insiders.
During the past 12 months, Artiva Biotherapeutics Inc has had a low of $1.78 and a high of $17.31. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 13.93, and a quick ratio of 13.93.
